Related references
Note: Only part of the references are listed.Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects
Elia Pancheri et al.
CANCERS (2020)
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients
Despina Fotiou et al.
BLOOD CANCER JOURNAL (2020)
Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials
Hamid Sayar et al.
LEUKEMIA RESEARCH (2019)
Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation
Ji Eun Park et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells
Song- Lee et al.
SCIENTIFIC REPORTS (2019)
Compound C Inhibits B16-F1 Tumor Growth in a Syngeneic Mouse Model via the Blockage of Cell Cycle Progression and Angiogenesis
Yun Taek Lee et al.
CANCERS (2019)
Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin
Panagiotis Efentakis et al.
BLOOD (2019)
Cutaneous melanoma: From pathogenesis to therapy (Review)
Giulia C. Leonardi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2
Sourav Banerjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Next-generation proteasome inhibitors for cancer therapy
Ji Eun Park et al.
TRANSLATIONAL RESEARCH (2018)
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Luca Falzone et al.
FRONTIERS IN PHARMACOLOGY (2018)
How UV Light Touches the Brain and Endocrine System Through Skin, and Why
Andrzej T. Slominski et al.
ENDOCRINOLOGY (2018)
Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma
Robert M. Hoffman
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Proteasome inhibitors in cancer therapy
Elisabet E. Manasanch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Chunying Song et al.
CANCER DISCOVERY (2017)
Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
Jae-Hyeon Kim et al.
CANCER RESEARCH AND TREATMENT (2017)
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
Bradley Garman et al.
CELL REPORTS (2017)
The Logic of the 26S Proteasome
Galen Andrew Collins et al.
CELL (2017)
'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors
Sophia Danhof et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Katrina Meeth et al.
PIGMENT CELL & MELANOMA RESEARCH (2016)
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design
Jil Schrader et al.
SCIENCE (2016)
Panobinostat for the Treatment of Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
The role of melanin pigment in melanoma
Radomir M. Slominski et al.
EXPERIMENTAL DERMATOLOGY (2015)
Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib
Wayne Harshbarger et al.
STRUCTURE (2015)
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines
Maria Cosenza et al.
HEMATOLOGICAL ONCOLOGY (2015)
Acute toxic effects of single dose dacarbazine: hematological and histological changes in an animal model
B. Milijasevic et al.
BIOTECHNIC & HISTOCHEMISTRY (2014)
Bortezomib for the treatment of non-Hodgkin's lymphoma
Prithviraj Bose et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
Amanda F. Baker et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Melanoma: Clinical Features and Genomic Insights
Elena B. Hawryluk et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
Molecular pathology of cutaneous melanoma
Leon C. van Kempen et al.
MELANOMA MANAGEMENT (2014)
Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Jennifer L. Thompson
ANNALS OF PHARMACOTHERAPY (2013)
Inhibition of platelet-derived growth factor receptor tyrosine kinase and downstream signaling pathways by Compound C
Hyun Jin Kwon et al.
CELLULAR SIGNALLING (2013)
Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells
Denis Selimovic et al.
CELLULAR SIGNALLING (2013)
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
Thomas M. Herndon et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome
Liang Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Flow cytometry based assays for the measurement of apoptosis-associated mitochondrial membrane depolarisation and cytochrome c release
Melinda E. Christensen et al.
METHODS (2013)
Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
Alastair J. King et al.
PLOS ONE (2013)
Apicidin induces endoplasmic reticulum stress- and mitochondrial dysfunction-associated apoptosis via phospholipase Cγ1-and Ca2+-dependent pathway in mouse Neuro-2a neuroblastoma cells
Ji Hyun Choi et al.
APOPTOSIS (2012)
Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy
Yan Zang et al.
CLINICAL CANCER RESEARCH (2012)
The unfolded protein response: controlling cell fate decisions under ER stress and beyond
Claudio Hetz
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Review of the Mammalian Unfolded Protein Response
Anirikh Chakrabarti et al.
BIOTECHNOLOGY AND BIOENGINEERING (2011)
CHEMOPREVENTION First line of defence
Lauren Gravitz
NATURE (2011)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Daniel Finley
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Targeting the ubiquitin system in cancer therapy
Daniela Hoeller et al.
NATURE (2009)
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines
A. Sorolla et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
NF-κB in the pathogenesis and treatment of multiple myeloma
Zhi-Wei Li et al.
CURRENT OPINION IN HEMATOLOGY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
Melanocyte biology and skin pigmentation
Jennifer Y. Lin et al.
NATURE (2007)
United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy
Robert C. Kane et al.
CLINICAL CANCER RESEARCH (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730)
RC Lilenbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proteasome inhibition as a novel therapeutic target in human cancer
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines
VO Melnikova et al.
ONCOGENE (2004)
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma
KI Amiri et al.
CANCER RESEARCH (2004)
Melanin pigmentation in mammalian skin and its hormonal regulation
A Slominski et al.
PHYSIOLOGICAL REVIEWS (2004)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β
T Nakagawa et al.
NATURE (2000)
Share Paper
